Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation

Korean Journal of Physiology and Pharmacology

Volumn 14, Issue 6, 2010, Pages 385-390

  Park, Jehyun ^a   Seo, Ji Yeon ^a   Ha, Hunjoo ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Antisense oligodeoxynucleotide; Matrix metalloproteinase; Mesangial cells; Plasmin; Plasminogen activator inhibitor 1

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FIBRONECTIN; GELATINASE A; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FLUOROMETRY; GENETIC TRANSFECTION; GLUCOSE INTAKE; GROWTH DISORDER; KIDNEY FIBROSIS; MESANGIUM; MESANGIUM CELL; NONHUMAN; PROTEIN SECRETION; RAT; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 79251518632     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: 10.4196/kjpp.2010.14.6.385     Document Type: Article

References (28)

1. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989;38:1077-1081.
2. Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol. 1995;9:104-111.
3. Wong AP, Cortez SL, Baricos WH. Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am J Physiol. 1992;263:F1112-F1118.
4. Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999;10:790-795.
5. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol. 2002;192:160-170.
6. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072.
7. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:1841-1850.
8. Ingelfinger JR. Forestalling fibrosis. N Engl J Med. 2003;349: 2265-2266.
9. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 2006;17:2999-3012.
10. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol. 2009;5:203-211.
11. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005;67:1762-1771. (Pubitemid 40577711)
12. Kitohing AR, Kong YZ, Huang XR, Davenport P, Edgtton KX, Carmeliet P, Holdsworth SR, Tipping PG. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol. 2003;14:1487-1495.
13. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001;60:587-596.
14. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005;67:1297-1307.
15. Collins SJ, Alexander SL, Lopez-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S, Eddy AA. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol. 2006;104:e23-e34. (Pubitemid 44238888)
16. Seo JY, Park J, Yu MR, Kim YS, Ha H, Lee HB. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta 1 during renal fibrosis in diabetes. Am J Nephrol. 2009;30:481-490.
17. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 2003;112:379-388.
18. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 2008;19:329-338.
19. Huang Y, Border WA, Lawrence DA, Noble NA. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol. 2009;297:F1045-F1054.
20. Neckers L, Whitesell L. Antisense technology: biological utility and practical considerations. Am J Physiol. 1993;265:L1-L12.
21. de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm. 2009;71:490-504.
22. Cho HK, Yang EK, Han HS, Lee WJ, Phillips ML. Effect of brain angiotensin II receptor antagonists and antisense oligonucleotide on drinking and renal renin in rats. Korean J Physiol Pharmacol. 2000;4:137-142.
23. Oh JH, Ha H, Yu MR, Lee HB. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int. 1998;54:1872-1878.
24. Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, Han DC, Uh ST, Park CS, Lee HB. Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun. 2003;309:961-966.
25. Fisher EJ, McLennan SV, Yue DK, Turtle JR. High glucose reduces generation of plasmin activity by mesangial cells. Microvasc Res. 1997;53:173-178.
26. Kanalas JJ, Hopfer U. Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol. 1997;8:184-192. (Pubitemid 127455872)
27. Gonzalez J, Klein J, Chauhan SD, Neau E, Calise D, Nevoit C, Chaaya R, Miravete M, Delage C, Bascands JL, Schanstra JP, Buffin-Meyer B. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis. Exp Biol Med (Maywood). 2009;234:1511-1518.
28. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem. 1994;269:14149-14152.